D J Nutt
Overview
Explore the profile of D J Nutt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
349
Citations
4542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lynskey M, Thurgur H, Athanasiou-Fragkouli A, Schlag A, Nutt D
Arch Suicide Res
. 2024 Jul;
:1-15.
PMID: 39045855
Objective: To document the prevalence and correlates of suicidal ideation (SI) among individuals seeking cannabis-based medicinal products (CBMPs); to test whether SI declines or intensifies after three months of CBMP...
2.
Nutt D, Peill J, Weiss B, Godfrey K, Carhart-Harris R, Erritzoe D
Curr Top Behav Neurosci
. 2023 Nov;
66:149-174.
PMID: 37955822
Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatment of depression. This chapter focusses on psychedelics that specifically target...
3.
Carhart-Harris R, Chandaria S, Erritzoe D, Gazzaley A, Girn M, Kettner H, et al.
Neuropharmacology
. 2022 Dec;
226:109398.
PMID: 36584883
This theoretical article revives a classical bridging construct, canalization, to describe a new model of a general factor of psychopathology. To achieve this, we have distinguished between two types of...
4.
Sakal C, Lynskey M, Schlag A, Nutt D
Psychopharmacology (Berl)
. 2021 May;
239(5):1147-1155.
PMID: 33970291
The therapeutic potential of medical cannabis to treat a variety of conditions is becoming increasingly recognised. Globally, a large number of countries have now legalised cannabis for medical uses and...
5.
Rolles S, Nutt D, Schlag A
Am J Bioeth
. 2021 Apr;
21(4):28-31.
PMID: 33825654
No abstract available.
6.
Erritzoe D, Roseman L, Nour M, MacLean K, Kaelen M, Nutt D, et al.
Acta Psychiatr Scand
. 2018 Jun;
138(5):368-378.
PMID: 29923178
Objective: To explore whether psilocybin with psychological support modulates personality parameters in patients suffering from treatment-resistant depression (TRD). Method: Twenty patients with moderate or severe, unipolar, TRD received oral psilocybin...
7.
Carhart-Harris R, Bolstridge M, Day C, Rucker J, Watts R, Erritzoe D, et al.
Psychopharmacology (Berl)
. 2017 Nov;
235(2):399-408.
PMID: 29119217
Rationale: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. Objectives: Here, we report on safety and efficacy outcomes for up to 6 months...
8.
Stroud J, Freeman T, Leech R, Hindocha C, Lawn W, Nutt D, et al.
Psychopharmacology (Berl)
. 2017 Nov;
235(2):459-466.
PMID: 29085980
Rationale: Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome. Objectives: The objective of this study is to investigate whether psilocybin,...
9.
Carhart-Harris R, Nutt D
J Psychopharmacol
. 2017 Sep;
31(9):1091-1120.
PMID: 28858536
Previous attempts to identify a unified theory of brain serotonin function have largely failed to achieve consensus. In this present synthesis, we integrate previous perspectives with new and older data...
10.
Savulich G, Riccelli R, Passamonti L, Correia M, Deakin J, Elliott R, et al.
Transl Psychiatry
. 2017 Mar;
7(3):e1054.
PMID: 28267152
Naltrexone is an opioid receptor antagonist used in the management of alcohol dependence. Although the endogenous opioid system has been implicated in emotion regulation, the effects of mu-opioid receptor blockade...